Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Authors
Category Primary study
JournalINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Year 2014
This article has no abstract
Epistemonikos ID: b7a6f46dfda40944f55d670536003f0c3029a3d9
First added on: Feb 06, 2025